PUBLISHER: Grand View Research | PRODUCT CODE: 1529631
PUBLISHER: Grand View Research | PRODUCT CODE: 1529631
The Asia Pacific advanced wound care market size is anticipated to reach USD 3.06 billion by 2030 and is projected to grow at a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of chronic wounds is the major factor contributing to the market growth. For instance, in January 2023, MiMedx Group, Inc., a prominent player in placental biologics, secured an exclusive distribution partnership with Gunze Medical Limited, a subsidiary of Gunze Limited, to market EPIFIX exclusively in Japan.
Improvements in healthcare infrastructure and surgical accessibility drive demand for advanced wound care solutions, spurred by increasing surgical procedures and the prevalence of chronic diseases and age-related conditions. According to the United Nations ESCAP (Economic and Social Commission for Asia and the Pacific), by 2023, the Asia Pacific region is expected to have approximately 697 million individuals aged 60 years or older, constituting approximately 60% of the global older population, with one in every seven individuals in the region falling into this age group. Projections indicated that by 2050, one in every four individuals in the region will be aged 60 years or older.
Moreover, the rising prevalence of chronic ailments such as diabetes, cancer, and autoimmune disorders is expected to elevate the occurrence of chronic wounds in the Asia Pacific region. According to the World Health Organization (WHO), within the WHO South-East Asia Region, diabetes affects over 96 million individuals, leading to significant economic burdens on patients, their families, healthcare systems, and national economies due to associated complications such as blindness, kidney failure, heart attacks, strokes, and lower limb amputations.